QT interval duration and dispersion in children and adolescents treated with ziprasidone (Q33159884)

23 July 2017

QT interval duration and dispersion in children and adolescents treated with ziprasidone (English)

1 reference

23 July 2017

1 reference

1

Christoph U Correll

1 reference

23 July 2017

5

John M Kane

1 reference

23 July 2017

Johnny D Lops

2

1 reference

23 July 2017

Vicki Figen

series ordinal

3

1 reference

23 July 2017

Anil K Malhotra

series ordinal

4

1 reference

23 July 2017

Peter Manu

series ordinal

6

1 reference

23 July 2017

8 March 2011

1 reference

The Journal of Clinical Psychiatry

23 July 2017

1 reference

23 July 2017

72

1 reference

23 July 2017

6

1 reference

23 July 2017

854-860

1 reference

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

23 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

From clinical research to clinical practice: a 4-year review of ziprasidone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Long QT syndrome: reduced repolarization reserve and the genetic link

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Drug-induced QT dispersion: does it predict the risk of torsade de pointes?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

New Generation Antipsychotic Drugs and QTc Interval Prolongation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

QT dispersion in nonsustained ventricular tachycardia and coronary artery disease.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

QT dispersion and components of the QT interval in ischaemia and infarction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

QT dispersion: an indication of arrhythmia risk in patients with long QT intervals

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Ziprasidone in adolescents with autism: an open-label pilot study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Electrocardiographic changes with ziprasidone.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3319445

Torsades de pointes associated with ziprasidone

31 October 2018

1 reference

12 December 2020

QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: the Manitoba Follow-Up Study

1 reference

12 December 2020

The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes

1 reference

12 December 2020

The QTc interval and its dispersion in patients receiving two atypical antipsychotics

1 reference

12 December 2020

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study

1 reference

12 December 2020

Identifiers

DOI

10.4088/JCP.10M05990YEL

1 reference

23 July 2017

1 reference

23 July 2017

1 reference